In a 64-year-old patient with a computed tomography coronary artery calcium score of 10, elevated low‑density lipoprotein cholesterol despite ezetimibe 10 mg daily, and who refuses statins and cannot obtain Repatha (evolocumab), what is the next best management?

Add Bempedoic Acid to Ezetimibe

Given this patient's statin intolerance, unavailable PCSK9 inhibitor access, and persistently elevated LDL-C of 215 mg/dL on ezetimibe alone, the next step is to add bempedoic acid 180 mg daily. This combination can achieve meaningful additional LDL-C reduction while avoiding the muscle-related side effects that preclude statin use.

Risk Stratification and Target

This 64-year-old patient with a CAC score of 10 falls into a moderate-to-high cardiovascular risk category requiring aggressive lipid management:

• CAC score of 10 indicates subclinical atherosclerosis and favors intensive lipid-lowering therapy, particularly in patients >55 years 1
• Target LDL-C should be <100 mg/dL for high-risk primary prevention, though <70 mg/dL would be more protective 1, 2
• Current LDL-C of 215 mg/dL represents a minimal 22 mg/dL reduction from baseline 193 mg/dL on ezetimibe—far short of the needed 50% reduction or absolute target

Why Bempedoic Acid is the Optimal Next Step

Bempedoic acid is specifically designed for statin-intolerant patients and offers several critical advantages in this scenario:

Efficacy Profile

• Reduces LDL-C by 15-25% when added to existing therapy 3
• In the CLEAR Outcomes trial, bempedoic acid reduced LDL-C by 29 mg/dL compared to placebo in statin-intolerant patients 3
• Reduced MACE by 13% in high-risk statin-intolerant patients 3
• When combined with ezetimibe, expect total LDL-C reduction of approximately 35-45% from baseline

Safety in Statin-Intolerant Patients

• Does NOT cause muscle-related side effects because it is specifically activated in the liver, not skeletal muscle 3, 4, 5
• Well-tolerated alternative for patients who cannot take statins 6, 4
• Oral administration (180 mg daily) offers convenience and likely better adherence than injectable therapies

Practical Considerations

• Available as oral therapy—no injection requirements
• Generic availability expected to improve cost-effectiveness
• Can be combined with ezetimibe without drug interactions 4, 5

Expected Outcome with Bempedoic Acid + Ezetimibe

Starting from baseline LDL-C of 193 mg/dL:

• Ezetimibe alone: ~20% reduction = 154 mg/dL (current 215 mg/dL suggests suboptimal response or adherence issue)
• Adding bempedoic acid: additional 15-25% reduction = expected final LDL-C of 115-130 mg/dL
• This would achieve a >30% total reduction and bring LDL-C closer to, though likely not fully achieving, the <100 mg/dL target

Alternative Strategies if Bempedoic Acid Unavailable

If bempedoic acid is not accessible or covered:

1. Aggressive Statin Rechallenge Protocol

Despite stated "unwillingness," attempt systematic statin rechallenge 7:

• Start with rosuvastatin 5 mg once weekly or atorvastatin 10 mg twice weekly
• Alternate-day dosing regimens can achieve meaningful LDL-C reduction with minimal muscle symptoms
• Document specific prior statin intolerances—many patients can tolerate at least one statin at low doses
• Consider coenzyme Q10 supplementation (though evidence is limited)

2. Bile Acid Sequestrants

• Colesevelam 3.75 g daily can provide additional 15-20% LDL-C reduction 8, 9
• Added to ezetimibe, could achieve target in this patient
• Major limitation: gastrointestinal side effects (bloating, constipation) and drug interactions
• Must be taken ≥2 hours before or ≥4 hours after ezetimibe 10

3. Inclisiran (if available)

• Small interfering RNA targeting PCSK9, administered subcutaneously every 6 months 4, 11, 5
• Similar efficacy to PCSK9 monoclonal antibodies (~50% LDL-C reduction)
• Advantage: dosing only twice yearly may improve adherence and potentially cost-effectiveness
• May have different insurance coverage than evolocumab/alirocumab

Critical Monitoring Points

Reassess LDL-C Response

• Recheck lipid panel in 8-12 weeks after adding bempedoic acid 7
• If LDL-C remains >100 mg/dL, escalate to PCSK9 inhibitor (appeal insurance denial with documentation of statin intolerance and inadequate response to dual therapy)

Monitor for Bempedoic Acid-Specific Adverse Effects

• Uric acid elevation: small subset of patients develop hyperuricemia 3
• Gout flares: increased incidence in CLEAR Outcomes 3
• Liver function tests: check at baseline and 8-12 weeks 3
• Tendon rupture: rare but reported; avoid in patients with history of tendon disorders

Address Adherence

The minimal LDL-C reduction (193→215 mg/dL suggests possible non-adherence or measurement variability):

• Confirm patient is actually taking ezetimibe 10 mg daily
• Consider fixed-dose combination products when available to improve adherence
• Reinforce dietary modifications (Mediterranean or DASH diet) 12

Common Pitfalls to Avoid

1. Accepting "statin unwillingness" without systematic rechallenge: Many patients labeled "statin intolerant" can tolerate low-dose or alternate-day regimens 7

2. Delaying therapy escalation: With CAC score >0 and LDL-C >200 mg/dL, this patient has established atherosclerotic risk requiring immediate intensive therapy 1

3. Ignoring the CAC score: CAC of 10 is NOT zero—it indicates subclinical disease and mandates treatment intensification, not deferral 1

4. Failing to appeal PCSK9 inhibitor denials: Document statin intolerance (specific agents tried, symptoms), inadequate response to ezetimibe + bempedoic acid, and high cardiovascular risk (CAC >0, LDL-C >200 mg/dL) for prior authorization 2